According to industry analyst Pharmanucleus, the global urothelial carcinoma treatment market is expected to witness robust growth during the forecast period from 2023 to 2030. The projected compound annual growth rate (CAGR) for the market is estimated to be around 20%. In 2022, the market was valued at USD 0.81 billion, and it is predicted to reach USD 3.48 billion by 2030.
According to Pharmanucleus, the tumor infiltrating lymphocytes (TILs) market is projected to grow significantly in the coming years. The market, which was valued at USD 9.17 billion in 2022, is anticipated to reach USD 25.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12.00% during the forecast period of 2023 to 2030.
The pediatric brain tumor market is growing at a CAGR of 6.8% over the forecast period and is expected to reach USD 1,843.7 million by 2022-2030. Pediatric brain tumor is an uncontrolled or abnormal growth of normal cells in the brain in children. Brain tumors are mainly of two types, cancerous (malignant) and non-cancerous (benign).
The global ovarian cancer market is expected to witness significant growth over the forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market. Multiple therapeutic landscapes and family history of ovarian cancer are seen as positive indicators of demand for new ovarian cancer drugs.
The Neuroendocrine Tumor Market is expected to witness market growth during the forecast period of 2023 to 2030. Pharmanucleusanalyzes that the market is growing with a CAGR of 10.4% during the forecast period of 2023 to 2030 and is expected to to reach USD 5,300.53 million by 2030.
The Global Neuroendocrine Carcinoma Treatment market is expected to reach US$ 1.7 billion by 2022, with a CAGR of 8.0% indicating favourable market expansion throughout the projected period.This report provides a comprehensive analysis of the global neuroendocrine tumor treatment market.
The HPV16 anogenital cancers market is projected to experience a high compound annual growth rate CAGR~1% from 2023 to 2030. This specialized sector of oncology focuses on the diagnosis, treatment, and management of anogenital cancers caused by HPV16, a high-risk strain of the human papillomavirus.
Hodgkin's lymphoma (HL) is a specific type of cancer affecting the lymphatic system, characterized by the presence of Reed-Sternberg cells in the lymph nodes. These abnormal cells play a crucial role in HL diagnosis. The HL market encompasses various products and services related to the diagnosis, treatment, and management of this disease.
Pharmanucleus, a research organization, has conducted an analysis on the projected growth rate of the global gastric cancer market for the forecast period of 2023-2030. According to their findings, the market is expected to experience a Compound Annual Growth Rate (CAGR) of approximately 16% during this period.
The global FGFR Positive Gastroesophageal Cancer Market size was valued at $YY million in 2022 and is projected to reach $YY million by 2030, growing at a high CAGR during the forecast period from 2023 to 2030.The FGFR (fibroblast growth factor receptor) positive gastroesophageal cancer market encompasses the pharmaceutical and biotechnology products specifically designed to target FGFR gene alterations in patients with gastroesophageal cancer.
The global ESR1 Mutation Metastatic Breast Cancer Diagnostics Market generated a Market Value of US$58.70 Million in 2022 and is expected to accumulate a Market Value of US$185 Million by registering a CAGR of 11% during the forecast period 2023 to 2030.
The global sarcoma market size was valued at $YY million in 2022 and is projected to reach $YY million by 2030, growing at a CAGR of 8.3% from 2023 to 2030.Epithelioid sarcoma is a rare and aggressive soft tissue sarcoma that primarily affects young adults. The market for epithelioid sarcoma treatment is relatively small due to its low incidence, presenting limited commercial opportunities for pharmaceutical companies.
The epithelial ovarian cancer market is growing steadily owing to the rising incidence of this malignancy. Epithelial ovarian cancer, the most common type of ovarian cancer, poses significant health risks to women worldwide. The market is driven by advances in treatment options such as surgery, chemotherapy, targeted therapy and immunotherapy which improve patient outcomes.
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market is a rapidly evolving sector within the field of lung cancer therapeutics. EGFR-NSCLC is a distinct subtype of non-small cell lung cancer characterized by specific genetic mutations affecting the EGFR gene.
The Endometrial Cancer Market is anticipated to reach USD 22,187.69 Million by 2030 at 4.20% CAGR during the forecast period 2023-2030. Endometrial cancer, commonly known as uterine cancer, is the abnormal development of endometrium cells in the uterus. Women with abnormal vaginal bleeding are diagnosed with endometrial cancer at an early stage.
The colorectal cancer market is expected to grow from US$ 18,619.3 million in 2023 to US$ 24,078.5 million by 2030; it is expected to grow at a CAGR of 3.3% from 2023 to 2030.Factors such as increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market.
Clear Cell Ovarian CancerMarket size was valued at USD 1.57 billion in 2021 and is poised to grow from USD 1.77 billion in 2022 to USD 9.67 billion by 2030, growing at a CAGR of 23.7% in the forecast period (2023-2030).Clear cell ovarian cancer is a rare subtype of ovarian cancer characterized by the presence of clear cells in the tumor. It accounts for approximately 5-10% of all ovarian cancer cases.
Chemotherapy Induced Peripheral Neuropathy Market is expected to reach US$1,174.26 million by 2030, from US$813.48 million in 2023; it is expected to register a CAGR of 5.4% from 2023 to 2030.Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent side effect that occurs as a result of treatment with antineoplastic agents.
The BRAF Mutant Metastatic Melanoma Market is projected to reach a high CAGR over the forecast period 2023 - 2030.The market for BRAF mutant metastatic melanoma treatment is highly competitive and dynamic. BRAF mutations are found in a significant proportion of melanoma patients, making it a crucial target for therapy.
The global bone metastasis market size was significantly robust in 2021 and is expected to register a rapid revenue CAGR over the forecast period. Bone metastasis market revenue growth is primarily driven by the rise in cancer incidences globally.Bone metastasis refers to the spread of cancer from its original location to the bones. This process, known as metastasis, is common in various types of cancer, with breast and prostate cancer exhibiting a higher propensity for bone metastasis.
The Bile Duct Cancer Market is anticipated to reach USD 198.4 Million by 2030 at 8.60% CAGR during the forecast period 2023-2030. Cholangiocarcinoma is a kind of cancer in which epithelial cells are altered, suggesting the growth of bile duct epithelial cells. Cancer's basic aetiology is unclear.
Adenoid cystic carcinoma (ACC) is a rare form of cancer that commonly affects the salivary glands and other secretory glands. The ACC market is characterized by limited treatment options and a lack of targeted therapies due to its complex biology. However, ongoing research and development efforts are focused on identifying novel treatment strategies, including targeted therapies and immunotherapies, to improve patient outcomes.
Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics MarketInsights The Acute Lymphoid/Lymphoblastic Leukemia (ALL) Therapeutics Market is expected to experience market growth during the forecast period of 2023 to 2030. Pharmanucleusanalyzes that the market is expected to grow at a CAGR of 5.25% during the above-mentioned forecast period. Rising prevalence of acute lymphoid/lymphoblastic leukemia (ALL) is driving the market for acute lymphoid/lymphoblastic leukemia (ALL) treatments.
The global nuclear medicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2030, growing at a CAGR of 11.3% from 2023 to 2030. The new research study is an examination of market industry trends. Industry trends, price analysis, patent analysis, conference and webinar materials, important players, and market buying behaviour are all included in the new research report.
The Ewing sarcoma market is estimated to increase at a CAGR of 6.30% between 2023 and 2030. The growing prevalence of Ewing sarcoma, improved awareness of the condition, and the discovery of novel treatment options are driving the market. Ewing sarcoma is a rare kind of soft tissue and bone cancer. It is most commonly diagnosed in children and teens, with a median age of 15 years old upon diagnosis.
Bladder Cancer Market Size was valued at USD 5.5 Billion in 2022. The Bladder Cancer market industry is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 Billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.60% during the forecast period (2023 - 2030).
The global CTLA-4 Therapies market is expected to reach USD 1384.4 million by 2030, at a CAGR of 7.1% during the forecast period 2022 to 2030. The modulation of cell motility and/or PI3 kinase signaling may also be other ways that CTLA-4 works. Early multiphoton microscopy investigations to observe T-cell movement in healthy lymph nodes seemed to support the
Cancer supportive care also known as palliative care is focused on relieving patients from the side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases, cancer treatments need to be stopped or the dose needs to be lowered due to various reasons such as low blood cell counts. In such cases, supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies.
When cells in the prostate gland begin to develop unnaturally and uncontrolled, it is called prostate cancer. The prostate is a gland found solely in males that produces some of the fluid found in sperm. Surgery, radiation, hormone therapy, chemotherapy, and other treatments are available for prostate cancer. Prostate cancer therapy is determined on the stage of the disease. Prostate cancer is treated by experts such as urologists, radiation oncologists, and medical oncologists.
The market size of the global?oncolytic virus therapies in the year 2019 is valued at 84.3 million and is predicted to reach 962 million by the year 2030 at an 26.28% CAGR during the forecast period.Oncolytic viruses (OVs) are either naturally occurring or genetically modified. They only target and kill cancer cells while leaving healthy cells unharmed. This treatment, a cutting-edge approach to treating cancer patients, has had positive outcomes. Oncolytic virus therapies, which target DNA or RNA inside or outside the body, overlap biomedical research fields with similar therapeutic goals. Through genetic modification, these therapies attempt to treat an illness. The need to treat these chronic illnesses and the rising cancer incidence are the main factors driving the market growth.
Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia.Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments.
Anal cancer is generally a rare type of malignancy that affects the colon and rectum. Some of the symptoms associated with anal cancer include anal or rectum bleeding, a lump near the anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. It can be caused due to several risk factors such as human papillomavirus (HPV) infection, excessive smoking, and medical history of vaginal, cervical, or vulvar cancers.
A breast cyst is a noncancerous (benign), fluid-filled sac in the breast. Developed as a result of fluid accumulation inside the breast glands, this is found in women aged 20 to 50 years and it can be single or multiple. A cyst may feel like a grape or water balloon or firm.
Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!
One of our marquee services We profile relevant start-up companies in the market.
Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.
Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.